XL147 clinical trials
Also written SAR245408.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses XL147 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2010 | 3 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Often tested with
Tested in the same studies.
XL765 (3) · Seribantumab (1) · Paclitaxel (1) · Carboplatin (1) · XL647 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses XL147 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination RegimenCompletedPhase 1/2SanofiNCT01587040Written as SAR245408How we know
- Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast CancerCompletedPhase 1/2SanofiNCT01082068Written as XL147 (SAR245408)How we know
- Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based RegimenCompletedPhase 1/2SanofiNCT01042925Written as XL147 (SAR245408)How we know
- Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial CarcinomaCompletedPhase 2SanofiNCT01013324Written as XL147 (SAR245408)How we know
- A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or LymphomaCompletedPhase 1SanofiNCT01943838Written as SAR245408How we know
- Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsWithdrawnPhase 1ExelixisNCT00704392Written as XL147How we know
- Safety and Pharmacokinetics of SAR245408 Daily Oral in Patients With Solid TumorsCompletedPhase 1SanofiNCT01392924Written as SAR245408How we know
- A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor CancersCompletedPhase 1SanofiNCT01436565Written as SAR245408How we know
- Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid TumorsCompletedPhase 1SanofiNCT00756847Written as XL147 (SAR245408),How we know
- Study of the Safety and Pharmacokinetics of XL147 (SAR245408) in Adults With Solid Tumors or LymphomaCompletedPhase 1SanofiNCT00486135Written as XL147 (SAR245408)How we know
- Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical ResectionCompletedPhase 1SanofiNCT01240460Written as XL147 (SAR245408)How we know
- Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid TumorsCompletedPhase 1SanofiNCT00692640Written as XL147 (SAR245408)How we know